目的:在患有终末期心力衰竭(HF)的肌营养不良(MD)患者中,由于MD相关肌无力的渐进性,持续流动左心室辅助装置(cf-LVAD)治疗仍存在争议.
方法:对2013年3月至2019年8月在我院行cf-VAD植入的所有MD患者进行回顾性研究。研究终点是死亡,由肌肉无力引起的主要LVAD相关并发症或呼吸功能障碍。
结果:共纳入11例MD患者(Becker型:n=6;Emery-Dreifuss肌营养不良:n=2;福山亚型:n=1;肢体带1B:n=2)。
方法:中位年龄41岁(IQR;29-47);日本机械辅助循环支持注册中位数:3级(2-3);MD诊断和LVAD植入之间的中位间隔为9年(6-18)。LVAD植入时的肺功能测试显示中位数为%VC;62%(45-82),FEV1%,82%(81-88)。出院生存率为100%,无肺部并发症和早期VAD相关并发症。在38个月(27-53)的中位随访中,由于设备感染需要重新入院(n=2),脑血管意外(致残,n=2和非禁用,n=2),室性心动过速(n=4),和右HF(n=3),分别。7名患者在中位等待时间为44个月(34-61)后成功接受了心脏移植;3名患者仍在等待名单上(等待时间:21、38和39个月)。一名患者在VAD植入后15个月死于右HF。在LVAD支持期间,没有人出现明显的肺功能障碍。
结论:在选定的晚期HFMD患者中,cf-LVAD治疗作为心脏移植的桥梁是一种可行的治疗选择。
OBJECTIVE: In muscular dystrophies (MD) patients with end-stage heart failure (HF), continuous flow left ventricular assist device (cf-LVAD) therapy is still controversial due to a progressive nature of MD-associated muscle weakness.
METHODS: All the MD patients who had cf- VAD implants between March 2013 and August 2019 in our hospital were retrospectively studied.
Study end points were death, major LVAD-associated complications or respiratory dysfunction caused by muscular weakness.
RESULTS: A total of 11 MD patients (Becker type: n = 6; Emery-Dreifuss Myodystrophy: n = 2; Fukuyama subtype: n = 1; Limb-girdle 1B: n = 2) were enrolled.
METHODS: median age 41 years (IQR; 29-47); median Japanese Registry for Mechanically Assisted Circulatory Support: level 3 (2-3); a median interval between MD diagnosis and LVAD implantation 9 years (6-18). The pulmonary function test at LVAD implantation showed a median of %VC; 62% (45-82), FEV1%, 82% (81-88). Survival to discharge was 100% without pulmonary complication and early VAD-related complications. During a median follow-up of 38 months (27-53), re-admissions were needed due to device infection (n = 2), cerebrovascular accidents (disabling, n = 2 and non-disabling, n = 2), ventricular tachycardia (n = 4), and right HF (n = 3), respectively. 7 patients received successful heart transplant after a median waiting time of 44 months (34-61); 3 patients are still on the waiting list (waiting time: 21, 38, and 39 months). One patient died of right HF 15 months after VAD implantation. No one had overt pulmonary dysfunction during LVAD support.
CONCLUSIONS: In selected MD patients with end-stage HF, cf-LVAD therapy is a viable therapeutic option as bridge to heart transplant.